Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

794 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Familial Mediterranean fever is no longer a rare disease in Japan.
Migita K, Izumi Y, Jiuchi Y, Iwanaga N, Kawahara C, Agematsu K, Yachie A, Masumoto J, Fujikawa K, Yamasaki S, Nakamura T, Ubara Y, Koga T, Nakashima Y, Shimizu T, Umeda M, Nonaka F, Yasunami M, Eguchi K, Yoshiura K, Kawakami A. Migita K, et al. Among authors: fujikawa k. Arthritis Res Ther. 2016 Jul 30;18:175. doi: 10.1186/s13075-016-1071-5. Arthritis Res Ther. 2016. PMID: 27473114 Free PMC article.
Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still's disease.
Asano T, Furukawa H, Sato S, Yashiro M, Kobayashi H, Watanabe H, Suzuki E, Ito T, Ubara Y, Kobayashi D, Iwanaga N, Izumi Y, Fujikawa K, Yamasaki S, Nakamura T, Koga T, Shimizu T, Umeda M, Nonaka F, Yasunami M, Ueki Y, Eguchi K, Tsuchiya N, Tohma S, Yoshiura KI, Ohira H, Kawakami A, Migita K. Asano T, et al. Among authors: fujikawa k. Arthritis Res Ther. 2017 Sep 12;19(1):199. doi: 10.1186/s13075-017-1406-x. Arthritis Res Ther. 2017. PMID: 28899403 Free PMC article.
Interleukin-6 targeting therapy in familial Mediterranean fever.
Fujikawa K, Migita K, Tsukada T, Umeda M, Nonaka F, Kawakami A, Eguchi K. Fujikawa K, et al. Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):150-1. Epub 2013 Sep 9. Clin Exp Rheumatol. 2013. PMID: 24064027 No abstract available.
Dysregulated mature IL-1β production in familial Mediterranean fever.
Migita K, Izumi Y, Fujikawa K, Agematsu K, Masumoto J, Jiuchi Y, Kozuru H, Nonaka F, Shimizu T, Nakamura T, Iwanaga N, Furukawa H, Yasunami M, Kawakami A, Eguchi K. Migita K, et al. Among authors: fujikawa k. Rheumatology (Oxford). 2015 Apr;54(4):660-5. doi: 10.1093/rheumatology/keu359. Epub 2014 Sep 19. Rheumatology (Oxford). 2015. PMID: 25240611
Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
Kawashiri SY, Nishino A, Suzuki T, Nakashima Y, Horai Y, Ueki Y, Aramaki T, Fujikawa K, Nakashima M, Okada A, Migita K, Mizokami A, Matsuoka N, Mine M, Sakito S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Aoyagi K, Eguchi K, Kawakami A. Kawashiri SY, et al. Among authors: fujikawa k. Clin Exp Rheumatol. 2016 Sep-Oct;34(5):808-812. Epub 2016 Jun 22. Clin Exp Rheumatol. 2016. PMID: 27384149
Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
Iwamoto N, Fukui S, Umeda M, Nishino A, Nakashima Y, Suzuki T, Horai Y, Nonaka F, Okada A, Koga T, Kawashiri SY, Fujikawa K, Aramaki T, Ichinose K, Hirai Y, Tamai M, Nakamura H, Terada K, Nakashima M, Mizokami A, Origuchi T, Eguchi K, Ueki Y, Kawakami A. Iwamoto N, et al. Among authors: fujikawa k. Mod Rheumatol. 2016 Sep;26(5):662-6. doi: 10.3109/14397595.2015.1129692. Epub 2016 Feb 16. Mod Rheumatol. 2016. PMID: 26708444
794 results